Signal transducers and activators of transcription (STATs) are transcription factors activated in response to cytokines and growth factors. Constitutively active Stat3 has been shown to mediate oncogenic transformation in cultured cells and induce tumor formation in mice. An increasing number of tumor-derived cell lines as well as samples from human cancer have been reported to express constitutively active Stat3 protein. We previously demonstrated that ovarian cancer cell lines express high levels of constitutively active Stat3. In this study, we show that inhibition of the Stat3 signaling pathway using the Janus Kinase-selective inhibitor, AG490, and a dominant negative Stat3 (Stat3b) signi®cantly suppresses the growth of ovarian and breast cancer cell lines harboring constitutively active Stat3. In the ovarian cancer cell lines, AG490 also diminished the phosphorylation of Stat3, Stat3 DNA binding activity, and the expression of Bcl-x L . Further, AG490 induced signi®cant apoptosis in ovarian and breast cancer cell lines expressing high levels of constitutively active Stat3 but had a less profound eect on normal cells lacking constitutively active Stat3. AG490 also enhanced apoptosis induced by cisplatin in ovarian cancer cells. These results suggest that inhibition of Stat3 signaling may provide a potential therapeutic approach for treating ovarian and breast cancers. Oncogene (2001) 20, 7925 ± 7934.
Introduction
Ovarian cancer is the most common cause of death from gynecologic neoplasms in the United States. Signi®cant progress has been made in identifying oncogenes and tumor suppressor genes involved in the pathogenesis of ovarian cancer, yet, the molecular mechanisms underlying this process are still poorly understood. Recently, with the delineation of important signal transduction cascades, it has become clear that the STAT pathway may play an important role in malignant transformation of several human cancers (Bromberg et al., 1999; Bowman et al., 2000; Turkson and Jove, 2000) .
STATs are transcription factors activated in response to cytokines and growth factors (Zhong et al., 1994; Darnell 1997) . Ligand dependent activation of STAT regulatory cascades is often associated with modulation of cell growth and dierentiation. Accordingly, the abnormal activation of STAT proteins is becoming more frequently associated with un-restricted cell growth and malignant transformation. In fact, a growing number of tumor-derived cell lines as well as samples from human cancer have been reported to contain constitutively activated STAT proteins, especially Stat3 (reviewed by Bowman et al., 2000; Turkson and Jove, 2000) . Stat3 has been classi®ed as an oncogene because the constitutively active Stat3 can mediate oncogenic transformation in cultured cells and tumor formation in nude mice (Bromberg et al., 1999) . Stat3 activation may not only provide a growth advantage, allowing accumulation of tumor cells, but also confer resistance to conventional therapies that rely on apoptotic machinery to eliminate tumor cells. The events downstream from constitutively active Stat3 that promote tumorigenesis are unclear but could include deregulation of cell cycle progression and/or providing protection against apoptosis. For example, constitutive activation of Stat3 signaling also confers resistance to apoptosis in human U266 myeloma cells and in other cells (Shen et al., 2001) .
We have previously demonstrated that constitutively active Stat3 is present in ovarian cancer cell lines but not in normal ovary surface epithelial cells . Moreover, in the ovarian cell lines that exhibited increased levels of constitutively active Stat3, there was signi®cantly greater induction of Stat-3 speci®c transcriptional activity and gene expression. We also demonstrated that these cell lines had elevated endogenous expression of Bcl-x L . The Bcl-x L protein, is a Bcl-2 family member that functions as an inhibitor of apoptosis Pan et al., 1998) . The overexpression of Bcl-x L inhibits chemotherapy-induced apoptosis (Dole et al., 1995; Liu et al., 1998) . The potential activation of Bcl-x L by activated Stat3 may provide an advantage for enhanced cell survival and chemoresistance in human ovarian carcinomas. Constitutive activation of Stat3 has also been demonstrated in breast carcinoma cells (Watson and Miller, 1995; Garcia et al., 1997; Bowman et al., 2000; Bromberg 2000; Page et al., 2000) . However, it is unclear whether constitutively active Stat3 signaling plays a role in the cell growth and the cell survival of ovarian and breast cancer cells. We reasoned inhibiting Stat3 pathways in ovarian and breast cancer cell lines may block constitutive Stat3 signaling and subsequently inhibit the abnormal cell growth and promote cell death in these cancer cells. In this study we examine the importance of the Stat3 pathway and explore whether inhibiting constitutively active Stat3 signaling result in growth inhibition and induction of apoptosis in ovarian and breast cancers.
Results

Phosphorylated JAK2 and Stat3 are present in ovarian cancer cells
Since there are no known genetic mutations or ampli®cations of Stat3 that have been associated with oncogenesis, we reasoned that an aberrant upstream signal may be responsible for the constitutive activation of Stat3 in ovarian cancer cell lines. We ®rst sought to determine whether Janus kinase 2 (JAK2), an upstream activator of Stat3, was highly phosphorylated in the ovarian cancer cell lines which have been shown to harbor constitutively active Stat3. As is demonstrated in Figure 1a , high levels of phosphorylated JAK2 were found in both MDAH2774 and Caov-3 ovarian cancer cell lines. Each of these cell lines expresses high levels of phosphorylated Stat3 (Figure 1a) . The constitutive activation of Stat3 in both MDAH2774 and Caov-3 ovarian cancer cell lines were con®rmed with the Stat3 dependent-transcriptional activity using the luciferase reporter construct that contains multimerized Stat3-speci®c binding sites . In contrast, A2780 ovarian cancer cells and normal human ovarian surface epithelial cells, both of which do not contain constitutively active Stat3, did not demonstrate an increased expression of phosphorylated JAK2 ( Figure  1a ). These results suggest that JAK2 may be one of the key upstream activators of Stat3 in these ovarian cancer cells. Moreover, the inhibition of JAK2 phosphorylation then provides a valuable tool for studying the JAK2/ Stat3 pathway in these cancer cell lines.
AG490 reduces the expression of Bcl-x L and phosphorylation of Stat3 in ovarian cancer cells
Constitutive activation of Stat3 may contribute to the up-regulation of Bcl-x L in ovarian cancer cell lines. The increased expression of the Bcl-x L induced by Stat3 would then provide a mechanism through which constitutively active Stat3 may contribute to the survival advantage of human ovarian carcinomas. The constitutive activation of Stat3 may also oer an explanation for the resistance to conventional chemotherapy in ovarian cancer cells that rely on the apoptotic pathway for chemotherapy induced cell death. We then examined whether the JAK-selective inhibitor, AG490, which has been shown to eectively block Stat3 signaling Nielsen et al., 1999; Ni et al., 2000) , could inhibit constitutive active Stat3, decrease the expression of Bcl-x L , and induce apoptosis in ovarian cancer cells. Treatment of Caov3 and MDAH2774, both which express high levels of JAK2 and Stat3, with AG490, but not negative control inhibitor A1, demonstrated a clear reduction in the level of Stat3 phosphorylation and Bcl-x L expression in both cell lines (Figure 1b,c) . The slight induction of phosphorylated Stat3 by 100 mM A1 in Caov-3 is non-speci®c, since we did not observe it in every experiment and did not observe it in MDAH2774 cells ( Figure 1c ). Treatment of AG490 also inhibited constitutive Stat3 speci®c DNA binding activity in MDAH2774 cells (Figure 1d ) and Caov-3 cells (data not shown) using an EMSA analysis. These results indicate that potentially blocking JAK2 pathway by AG490 dramatically reduces phosphorylated Stat3 and Stat3 DNA binding activity.
Inhibition of Stat3 signaling with AG490 and the ectopic expression of a dominant-negative Stat3 construct suppresses cell growth and colony formation in ovarian cancer cells
We next examined the eects of AG490 on cell growth in MDAH2774 and Caov-3 ovarian cancer cell lines. Treatment with AG490 signi®cantly inhibited growth in both cancer cell lines as compared to treatment with A1 (Figures 2a and 3a) . These results suggest that AG490 is a potent growth inhibitor of ovarian cancer cells that express constitutively active JAK2 and Stat3. To further investigate the role of Stat3 activation in the cell cycle regulation of ovarian cancer cell lines, a dominant-negative Stat3 (Stat3 b) construct was introduced into the MDAH2774 and Caov-3 cell lines. The stable transfection of this construct signi®cantly inhibited colony formation as determined by the reduction of G418 resistant colonies when compared to cells transfected with pcDNA3 vector alone (Table  1) . We, however, were unable to detect higher levels of Stat3b protein expression in stable G418 colonies transfected with Stat3b than cells transfected with pcDNA3 vector alone (data not shown). It is possible that inhibition of constitutively active Stat3 signal by Stat3b is lethal to these cancer cells. Therefore, none of the G418 colonies may tolerate high levels of Stat3b protein expression. These results, taken together, suggest that constitutively active Stat3 signaling plays an important part in the abnormal cell proliferation observed in ovarian cancer cell lines, and that inhibition of this pathway results in the signi®cant suppression of cell growth.
AG490 induces apoptosis in ovarian cancer cells
Treatment with AG490 signi®cantly inhibited cell growth in ovarian cancer cell lines (Figures 2a and  3a) . To further examine whether AG490 induces apoptosis in these cancer cells, Caov-3 and MDAH2774 cells were treated with 50 mm of A1 or AG490. Considerable induction of apoptosis (39 ± 50%) was observed on 3 and 4 days after AG490 treatment in both cancer cell lines (Figures 2b and 3b) . As negative controls, untreated cells and A1 treated cells, only minimal induction of apoptosis were observed ( Figures  2b and 3b) . By days 5 and 6 following AG490 treatment, greater than 60 to 75% of the Caov-3 ( Figure 2b ) and MDAH2774 (Figure 3b ) cells lost cell viability by apoptosis. Induction of apoptosis by AG490 in ovarian cancer cells was also supported by the cleavage of pro-caspase-3 (data not shown).
Together, these results demonstrate that AG490 downregulates phosphorylation of Stat3, constitutive Stat3 DNA binding activity, Bcl-x L expression, inhibits cell proliferation, and induces apoptosis in ovarian cancer cells expressing constitutively active Stat3.
AG490 enhances apoptosis induced by cisplatin in ovarian cancer cells
As stated above, the constitutive activation of Stat3 may contribute to the up-regulation of Bcl-x L in cancer cell lines (Bromberg et al., 1999; Catlett-Falcone et al., 1999) . The activation of the Bcl-x L pathway by Stat3 would then provide a mechanism through which constitutively activated Stat3 may contribute to the survival advantage of human carcinomas. The constitutive activation of Stat3 may also oer an explanation for the resistance to conventional chemotherapy in ovarian cancer cells that rely on the One hundred mg of total proteins from the cell lysates was subjected to 8% sodium dodecyl sulfatepolyacrylamide gel electrophoresis and then transferred to a nitrocellulose membrane. The membranes were blotted with phospospeci®c Stat3, phospo-speci®c JAK2 or GADPH antibody. Eect of AG490 on Stat3 phosphorylation and Bcl-x L expression in (b) Caov-3 and (c) MDAH2774 ovarian cancer cells. Cells were cultured in medium containing 5% FBS and treated with the AG490 or A1 at concentrations of 50 and 100 mM for 48 h. Cell lysates were separated by 8 or 15% SDS polyacrylamide gel electrophoresis. Each gel was analysed with Stat3, Bcl-x L , or phospho-speci®c Stat3 antibodies. (d) Eect of AG490 on Stat3 speci®c DNA binding activity in cell extracts from control and AG490-treated MDAH2774 cells using radiolabeled double-stranded Stat3 consensus binding motif as described in Materials and methods apoptotic pathway for chemotherapy induced cell death. Therefore, we reasoned that the inhibition of constitutively active Stat3 in ovarian cancer cell lines with AG490 may decrease the expression of Bcl-x L and enhance the apoptosis induced by cisplatin. To test this hypothesis, MDAH2774 cells were treated with cisplatin, AG490, and a combination of the two drugs. Though both cisplatin and AG490 induced a considerable amount of apoptosis by day 3 and day 4, the combination of the two chemotherapeutic agents resulted in signi®cantly greater cell death ( Figure 3c ). More speci®cally, by day 4 following treatment with the combination of cisplatin and AG490, greater than 65% of the MDAH2774 cells were undergoing apoptosis ( Figure 3c ). These results suggest that AG490 in combination with standard chemotherapeutic agents used to treat ovarian cancer may lead to enhanced chemosensitivity and greater tumor reduction. The results also suggest that using a combination of AG490 and other cytotoxic compounds may oer a mechanism for reducing the therapeutic doses of chemotherapy regimens and, thus, limiting the unwanted clinical side eects patients often experience in the clinical setting.
AG490 demonstrates minimal induction of apoptosis in normal ovarian surface epithelial cells and normal human skin fibroblasts
The bene®ts of cytotoxic chemotherapy are often attenuated by damage to normal cells. Dose limiting side eects on unaected tissues and organs unfortunately compromise the capability of cancer treatments to both reduce tumor burden and eradicate metastatic disease. For this reason, we sought to determine the eects of AG490 on cancer cells versus normal cells. Human ovarian surface epithelial cells (HOSEC), normal human skin ®broblasts (NHSF), Caov-3, and MDAH2774 cells were treated with either A1 or AG490 at a concentration of 50 mm. Both HOSEC and NHSF lack constitutively active Stat3 . Consistent with our previous ®ndings, AG490 signi®cantly inhibited the growth of Caov-3 and MDAH2774 ovarian cancer cells (Figures 2a and  3a) . However, NHSF were resistant to AG490 induced growth inhibition and morphological changes ( Figure  4b ). More importantly, when compared to MDAH2774 cells, HOSEC and NHSF, which lack constitutively active Stat3, are resistant to apoptosis induced by AG490 (Figure 4a ).
Inhibition of cell growth and induction of apoptosis by AG490 in MDA-MB-468 breast cancer cell line
The constitutive activation of Stat3 has been demonstrated in breast cancer (Watson and Miller, 1995; Garcia et al., 1997; Bowman et al., 2000; Page et al., 2000) . Based on the results we observed in ovarian cancer cell lines and recent data demonstrating that AG490 inhibited the constitutive activation of Stat3 and suppressed the growth of prostate cancer cells (Ni et al., 2000) , we then determine whether AG490 also 5 cells per 100-mm dish for 24 h before treatment. The cells were treated with 50 mm of A1 or AG490. Cells were subsequently stained with Propidium Iodide (PI) on days 1 through 6 after treatment and analysed for sub-G1 peaks using a¯ow cytometer. The results are given as averages with standard deviations from at least three independent experiments inhibits cell growth and induces apoptosis in breast cancer. We chose to use MDA-MB-468, a breast cancer cell line known to exhibit constitutively active Stat3 (Garcia et al., 1997) in this study. Similar to the results that we observed in the MDAH2774 and Caov-3 ovarian cancer cell lines, AG490 inhibited cell growth in the MDA-MB-468 cells as compared to the control cells. By day 6, there was nearly 15-fold reduction in the total number of viable cells treated with AG490 when compared to untreated cells (Figure 5a ). Stable transfection of Stat3b construct also signi®cantly inhibited colony formation in MDA-MB-468 cells as similar to the inhibitory eect in MDAH2774 and Caov-3 cells (Table 1) . We subsequently examined whether loss of viability following AG490 treatment is due to induction of apoptosis in this cell line. By day 4, 40% of the cells treated with AG490 had undergone apoptosis. By day 6, 70% of the cells in the AG490 treatment groups were apoptotic (Figure 5b) . Finally, to study the potential adverse eects AG490 may have on normal breast tissue, we compared treatment with AG490 to treatment with A1 and no treatment in the normal breast cell line MCF-10A. There was no signi®cant dierence in the fraction of apoptotic cells induced in the cells treated with AG490 as compared to the untreated cells (Figure 5c ). Our ®ndings suggest that Stat3 signaling may play an important role in 5 cells per 100-mm dish for 24 h before treatment. The cells were treated with 50 mm of A1 or AG490. Cells were subsequently stained with Propidium Iodide (PI) on days 1 through 6 after treatment and analysed for sub-G1 peaks using a¯ow cytometer. (c) MDAH2774 were seeded at 2610 5 per 100-mm dish for 24 h before treatment. The cells were ®rst treated with 25 mm of AG490. Twenty-four hours later the cells were then treated with cisplatin (1 mg/ml). Treated cells were subsequently stained with PI on days 3 and 4 after treatment and analysed for sub-G1 peaks using a¯ow cytometer. Results are given as standard deviations from three independent experiments 
Inhibition of colony formation by a dominant-negative Stat3 construct (Stat3b). To examine the inhibitory eect of Stat3b, ovarian cancer cell lines, Caov-3, MDAH 2774 and breast cancer cell line, MDA-MB-468, were transfected with 10 mg of PcDNA3 vector alone or dn Stat3 cDNA linked in cis on a plasmid with a G418 resistant marker*. Stable G418-resistant colonies were selected for 2 to 3 weeks. G418 colonies were then stained and counted. The results are given as averages from two to three independent experiments.
breast cancer progression and that AG490 is an eective inhibitor of cell growth as well as a potent induction agent for cell death in breast cancer cell lines expressing constitutively active Stat3. Additionally, AG490, at a dose at which it is an eective inhibitor of both ovarian and breast cancer cells, appears to have no adverse eects on normal ovary and breast cells which lack constitutively active Stat3 (Figures 4a  and 5c ).
Discussion
STATs were originally discovered as latent cytoplasmic transcription factors responsible for mediating cellular responses to a diverse number of cytokines and growth factors (Zhong et al., 1994; Darnell, 1997) . However, the molecular mechanisms through which Stat proteins, speci®cally Stat3, aect cellular function or induce cellular transformation have yet to be fully de®ned. Stat3 de®cient mice die early in embryogenesis, often prior to gastrulation (Akira, 1999) . However, using a Cre-loxP recombination system, Akira (2000) were able to show that Stat3 plays a crucial role in regulating cell growth, anti-apoptosis and cell motility. Multiple reports also have suggested that constitutively active Stat3 is an important aspect of a diverse group of malignancies. Evidence supports that constitutively activated Stat3 signaling contributes to the pathogenesis of multiple myeloma through an inhibition of apoptosis . Similarly, cells derived from human prostate cancers have been demonstrated to harbor constitutively activated Stat3, a ®nding that correlated with the malignant potential of the cells (Ni et al., 2000) . It has also been shown that Stat3 is constitutively activated in several types of cancers, including head and neck tumors (Bowman et al., 2000; Song and Grandis, 2000) .
In the present study, we provide evidences that Stat3 activation may play an important role in regulating ovarian and breast cancer cell growth and survival. In our previous study, we demonstrated that Stat3 is constitutively activated in ovarian cancer cell lines and this activation leads to an increase in Stat3-speci®c transcriptional activity . We also showed an increased expression of Bcl-x L and cyclin D1 in cell lines containing elevated levels of phosphorylated Stat3 and Stat3 transcription activity . These results are consistent with data demonstrating that murine cells overexpressing constitutively active Stat3 also express high levels of cyclin D1 and Bcl-x L (Bromberg et al., 1999) . However, the molecular mechanisms through which Stat3 is constitutively activated in ovarian cancer cells remain unclear. There are similar levels of total Stat3 protein expressed in all the ovarian cancer cell lines we Figure 4 Eect of AG490 on normal cells. (a) MDAH2774 cells, HOSEC, and NHSF were seeded and treated with AG490 as described in Materials and methods. Cells were subsequently stained with PI on day 3 after treatment. The amount apoptosis was analysed with sub-G1 peaks using a¯ow cytometer. The fold increase of apoptosis was given by the ratio of percentage of apoptosis in cells treated with AG490 to those of untreated cells. (b) Caov-3 cells and NHSF were seeded at a density of 1610 5 cells per 60-mm dish in DMEM medium supplemented with 5% fetal bovine serum for 24 h before treatment with 50 mM of AG490. On day 3 following treatment, cells were photographed (2006) using the Leitz microscope and a Wild MPS photoautomat examined. However, only some of the cell lines express high levels of phospho-Stat3 . This ®nding suggests that the constitutive activation of Stat3 may not be due to the overexpression of total Stat3, but rather a result of phosphorylation of the protein modulated by upstream regulator(s).
Though the upstream eectors of Stat3 are not completely understood, JAKs are believed to be responsible for the tyrosine phosphorylation of Stat3 in response to growth factors and cytokines, as well as in Src-transformed cells (Briscoe et al., 1996; Campbell et al., 1997; Zhang et al., 2000; Zong et al., 2000) . We hypothesized, therefore, that the Stat3 phosphorylation and activation in ovarian cancer cell lines may be due to the constitutive activation of the upstream signals translated by JAKs or through aberrancies in the JAKs themselves. Accordingly, in this study, we demonstrated that high levels of phosphorylated JAK2 are present in both MDAH2774 and Caov-3 ovarian cancer cells (Figure 1a) and that AG490, a JAKselective inhibitor, reduces phosphorylated Stat3, Stat3 DNA binding activity, and the expression of Bcl-x L in these cancer cells (Figure 1 ). These results suggest that Jak2 may be one of the key upstream activators of Stat3 in these cancer cells. The mechanism that activated JAK2 constitutively in both MDAH2774 and Caov-3 ovarian cancer cell lines is unknown. However, it has been shown that SOCS-1 (Suppressor of cytokine signaling), a negative regulator of the JAK/ STAT pathway, is silenced by methylation in human hepatocellular carcinoma (Yoshikawa et al., 2001) . The restoration of SOCS-1 shows growth-suppression activity in which SOCS-1 was methylation-silenced and JAK2 was constitutively activated. It is interesting to study whether ovarian cancer cell lines or tumor specimens that express high levels of phospho-JAK2, SOCS-1 is silenced. Methylation of this gene's promoter in ovarian cancers may potentially activate JAK2 and Stat3 constitutively. Another candidate for an upstream regulator of Stat3 is c-Src (Zhang et al., 2000; Zong et al., 2000) . Activation of Src kinase in ovarian cancers have been reported (Budde et al., 1994 ; 5 cells per 100-mm dish in DMEM medium supplemented with 5% FBS for 24 h before treatment. The cells were treated with 50 mm of A1 or AG490. Cells were subsequently stained with PI on days 4 and 6 after treatment and analysed for sub-G1 peaks using a¯ow cytometer. (c) A similar experiment was carried out using the normal breast cells, MCF-10A, and the MDA-MB-468 cells on day 4 after treatment to compare the potential deleterious eects of AG490 on normal breast cells. The fold increase of apoptosis was given by the ratio of percentage of apoptosis in cells treated with AG490 or A1 to those of untreated cells Wiener et al., 1999) . It will be interesting to examine whether c-Src is also activated in ovarian cancer cells and tumor specimens expressing constitutively active Stat3.
AG490 also results in signi®cant apoptosis in MDAH2774 and Caov-3 ovarian cancer cells and in MDA-MB-468 breast cancer cells. Similar reduction of constitutive Stat3 DNA binding activity and growth inhibition by AG490 in MDA-MB-468 cells were also reported (Garcia et al., 2001) . MDA-MB-468 cells express high levels of epidermal growth factor receptor (EGFR) (Sartor et al., 1997) . AG490 may inhibit EGFR to activate Stat3 through the inhibition JAKs in this cell line as suggested (Garcia et al., 2001 ). The precise mechanism(s) through which AG490 induces apoptosis is unclear. One of the potential mechanisms that may be involved is the down-regulation of Bcl-x L mediated by the inhibition of the JAK2/Stat3 pathway. The promoters of human Bcl-x genes harbor multiple Stat3-binding sites, named acute-phase response elements or APRE sequences . Additionally, blocking Stat3 signaling in both multiple myeloma cells in vitro and head and neck xenografts down-regulated Bcl-x L expression and result in a dramatic induction of programmed cell death (Song and Grandis, 2000; Catlett-Falcone et al., 1999) . Further, dysregulation and imbalance of the Bcl-2 family of proteins has been shown to confer resistance to apoptosis induced by both physiological signals and chemotherapeutic drugs (Dole et al., 1995; Minn et al., 1995; Liu et al., 1998) . Ovarian cancer cells expressing Bcl-x L have also been found to be highly resistant to cisplatin and Taxol when compared to controls (Liu et al., 1998) . Similarly, our results also demonstrate that AG490 down regulates Bcl-x L levels and induces apoptosis. Thus, like the data presented for multiple myeloma and other cancers, our ®ndings suggest that Bcl-x L may be one of the important survival factors in ovarian cancer cells that express constitutively active Stat3. Moreover, blocking Stat3 signaling may also induce apoptosis independent of down regulation of Bcl-x L (Epling-Burnette et al., 2001; Niu et al., 2001) .
Further, we demonstrated that inhibition of constitutively active Stat3 using the ectopic expression of a dominant-negative Stat3 (Stat3b) signi®cantly suppressed colony formation of ovarian and breast cancer cells. These results suggest that in ovarian and breast cancer cells expressing constitutively active Stat3, this cellular pathway may be essential for proliferation and survival. Inhibition of Stat3 signaling with AG490 or Stat3b may represent a novel method for inducing signi®cant cell death and growth inhibition in ovarian and breast cancer using an in vivo model. We also demonstrated that AG490 selectively inhibits ovarian and breast cancer cells while having a less profound eect on normal human cells that lack constitutively active Stat3 (Figures 4 and 5c) . Similarly, the eects AG490 and Stat3b have on the JAK/STAT pathway seem to translate into minimal deleterious eects in hematopoetic and other normal cell lines (Meydan et al., 1996; Niu et al., 1999) . One possible mechanism for the increased sensitivity of cancer cells is that malignant cells with constitutively active Stat3 may have become dependent upon this pathway to sustain their growth and survival. In contrast, normal cells may be able to use alternative pathways to compensate for loss of Stat3 signaling. These results suggest that normal cells, which lack constitutively active Stat3, may be resistant to Stat3-targeted therapy. Thus, our ®ndings, as well as that of others, suggest that inhibition of the Stat3 pathway by AG490 and Stat3b, both which have minimal eects on normal human cells, may oer a treatment option with a potentially high therapeutic index for ovarian cancer.
Finally, high levels of Bcl-x L expression in ovarian cancer cells as well as in other types of malignant cell lines can confer resistance to programmed cell death induced by chemotherapeutic agents (Dole et al., 1995; Minn et al., 1995; Liu et al., 1998) . Therefore, constitutive activation of Stat3 signaling in ovarian cancers, through the up-regulation of Bcl-x L , may confer resistance to apoptosis induced by chemotherapeutic agents. Thus, blocking the Stat3 signaling pathway in drug-resistant cancer cells using AG490 or Stat3b may down regulate Bcl-x L expression and resensitize ovarian cancer cells to the toxic eects of taxol and cisplatin. Such an approach may not only reduce the adverse side eects associated with conventional, aggressive chemotherapeutic agents, but also may improve the overall response rate and survival in women with ovarian and breast cancers.
Materials and methods
Cell culture
The human ovarian carcinoma cell lines, Caov-3 and MDAH2774, and the human breast cancer cell line, MDA-MB-468, were obtained from the American Type Culture Collection (Manassas, VA, USA). A2780 ovarian cancer cells were derived from a previously untreated patient isolated by investigators at Fox Chase Cancer Center. Normal human skin ®broblasts (NHSF), obtained from Mats Ljungman at the University of Michigan, express a low level of constitutively active Stat3 . These cell lines were maintained at 378C under a 5% CO 2 environment in Dulbecco's Modi®ed Eagle's medium (DMEM, Gibco/BRL, Grand Island, NY, USA), enriched with 10% fetal bovine serum (FBS, Gibco/BRL) and antibiotics (5000 units/ml penicillin G, 5000 mg/ml streptomycin; Gibco/BRL). Human ovarian surface epithelial cells (HOSEC) were collected at the University of Michigan Medical Center using the scrape technique at the time of operative procedure as previously described . Cell specimens were propagated in medium 199 with MCDB 105 (1 : 1, Sigma) supplemented with 15% FBS. The normal human breast cell line, MCF-10A, was provided by Stephen Ethier at the University of Michigan, also expresses a low level of constitutively active Stat3 (Garcia et al., 1997) . This cell line was maintained in Ham's F-12 serumfree medium supplement with 5 mg/ml of insulin, 1 mg/ml of hydrocortisone and 10 ng/ml of epidermal growth factor (Gibco/BRL).
Western blot analysis
Caov-3 and MDAH2774 cells were treated with the JAKselective inhibitor, AG490, or inactive inhibitor to JAKs, A1, as a negative control (Calbiochem, San Diego, CA, USA) at concentrations of 50 and 100 mM for 48 h. To reduce the basal phosphorylation of Stat3 serum concentrations were reduced to 5% when AG490 or A1 was added. Expression of phosphorylated Stat3, Bcl-x L , and caspase-3 was examined 48 h following treatment. Quanti®cation of total protein concentrations in the cell lysates was determined by the Bio-Rad Bradford assay. For Western blotting analysis, 100 mg of total proteins from the cell lysates was subjected to 8 or 15% sodium dodecyl sulfatepolyacrylamide gel electrophoresis and then transferred to a nitrocellulose membrane. Membranes were immuno-blotted using phospo-speci®c Stat3, phospho-independent Stat3 (Cell Signaling Tech., Beverly, MA, USA), Stat3 C-terminal speci®c (to recognize full-length of Stat3) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), phospo-speci®c JAK2 (Upstate Biotechnology, Lake Placid, NY, USA), Bcl-x L (BD Transduction Labs, Lexington, KY, USA), cleaved caspase-3 (BD Pharmingen, San Diego, CA, USA) and GADPH (Chemicon International Inc., Temecula, CA, USA) antibodies. Phosphoindependent Stat3 antibody recognizes both full-length and Stat3b proteins. Stat3 C-terminal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) only recognizes fulllength of Stat3. Proteins were detected using the enhanced chemiluminescence (ECF) system (Amersham Life Science, Arlington Heights, IL, USA) and a Molecular Dynamics (Sunnyvale, CA, USA) Storm PhosphorImager.
Eletrophoretic mobility shift assay (EMSA)
Stat3 speci®c DNA binding were performed as described previously (Gracia et al., 1997; Ni et al., 2000) . MDAH2774 and Caov-3 cells were either untreated or treated with the AG490 or A1 at concentrations of 50 and 100 mM for 72 h. Cell extracts were then prepared by lysing cells in a high-salt buer (20 mM HEPES (pH 7.9), 20 mM NaF, 1 mM Na 4 P 2 O 7 , 1 mM Na 3 VO 4 , 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 0.5 mM phenylmethylsulfonyl¯uoride, 420 mM NaCl, 20% glycerol, 1 mg/ml complete protease inhibitor (Roche Molecular Biochem., Indianapolis, IN, USA)), followed by snapfreezing in ethanol/dry ice for 5 min and thawing on ice for 10 min as previously described (Ni et al., 2000) . The freeze and thaw procedures were repeated again for a total of two times. The supernatant was then clari®ed by centrifugation at 14 000 r.p.m. for 10 min at 48C. Protein concentrations were determined by using the protein assay kit (Bio-Rad, Hercules, CA, USA) according to the manufacturer's protocol. Nuclear extracts (20 mg) were incubated in a ®nal volume of 20 ml of 10 mM HEPES (pH 7.9), 80 mM NaCl, 10% glycerol, 1 mM DTT, 1 mM EDTA, and 100 mg/ml of sonicated poly(deoxyinosinic-deoxycytidylic acid) and analysed by EMSA with radiolabeled double-stranded Stat3 consensus binding motif 5'-GATCCTTCTGGGAATTCCTAGATC (Santa Cruz Biotechnology, Santa Cruz, CA) for 20 min at room temperature. The protein-DNA complexes were resolved on a 4.5% nondenaturing polyacrylamide gel containing 2.5% glycerol in 0.256 Tris-borate EDTA under 120 volts for 1.5 h at room temperature and the results were autoradiographed.
DNA transfection and colony formation assay
The PcDNA3-Stat3b vector, generously provided by Richard Jove at the H. Lee Mott Cancer Center, contains a dominant-negative Stat3 (Stat3b) construct. Stat3b is a naturally occurring isoform (short form) of Stat3 that lacks an internal domain of 50 base pairs located near the Cterminus (Caldenhoven et al., 1996) . This splice variant has been shown to have the properties of a strong dominantnegative regulator of Stat3 transcriptional activity (Caldenhoven et al., 1996) . MDAH2774, Caov-3 ovarian cancer cells and MDA-MB-468 breast cancer cells were transfected with PcDNA3 vector alone or Stat3b cDNA linked in cis on a plasmid with a Geneticin (G418) resistance marker. Individual cell clones were selected and grown in medium containing 600 mg per ml of the antibiotic G418 (Gibco/ BRL) for 2 ± 3 weeks. The G418 resistant colonies were further stained with 0.5% crystal violet and counted. The inhibition of growth by the ectopic expression of Stat3b was determined by the reduction of G418-resistant colony numbers. The values are given as averages with standard deviations from three independent experiments.
Cell growth assay and morphological assessment
For cell growth assays, MDAH2774 and Caov-3 ovarian cancer cells and NHSF cells were seeded at a density of 1610 5 cells per 60-mm dish. The breast cancer cell line, MDA-MB-468, was seeded at a density of 2610 5 cells per 60-mm dish. All cell lines were maintained in DMEM medium supplemented with 5% FBS for 24 h before treatment. Cells were then treated with 50 mm of AG490 or A1 (Calbiochem, La Jolla, CA, USA). Cell numbers were counted with Trypan blue staining on days 2, 4, and 6 following treatment. The results are given as averages with standard deviations from three independent experiments. On day 3 after treatment, Caov-3 cells and NHSF were photographed (2006) using a Leitz Labovert microscope and a Wild MPS photoautomat (W Nuhsbaum, Inc., McHenry, IL, USA).
Apoptosis assay
Cancer and normal cells were seeded at 3610 5 cells per 100-mm dish or 1610 5 cells per 12-well plates in triplicate for 24 h before treatment. The cells were treated with 50 mm of A1 or AG490. Cells were harvested, ®xed with 100% alcohol, and stained with Propidium Iodide (PI) as described previously. In this assay, the nuclei of apoptotic cells exhibit a sub-G1 pro®le characteristic of DNA fragmentation. Analysis was performed using software on a FACScan¯ow cytometer (Becton Dickinson, San JoseÂ , CA, USA). For the cisplatin treatment, MDAH2774 were seeded at 2610 5 per 100-mm dish for 24 h before treatment. The cells were ®rst treated with 25 mm of AG490. Twenty-four hours later the cells were then treated with cisplatin (1 mg/ml). Treated cells were subsequently stained with PI on days 3 and 4 after treatment and analysed for sub-G1 peaks using a¯ow cytometer. Results are based on averages and standard deviations from three separate experiments.
